ArticleAddiction biology2013
Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone.
Article in Addiction biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks.Current drug safety · 2025Review
- Article
- Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.MedComm · 2022Review
- Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis.Molecular psychiatry · 2021Article
- From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.Trends in endocrinology and metabolism: TEM · 2021Review
- Reactive mesoporous silica nanoparticles loaded with limonene for improving physical and mental health of mice at simulated microgravity condition.Bioactive materials · 2020Article
- Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons.Molecular psychiatry · 2020Article
- The μ-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers.Brain and behavior · 2020Article
- Current status of opioid addiction treatment and related preclinical research.Science advances · 2019Review
- Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice.Psychopharmacology · 2018Article
- The μ-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment.Pharmacogenomics · 2017Article
- Convergent Balancing Selection on the Mu-Opioid Receptor in Primates.Molecular biology and evolution · 2017Article
- Opioid endocrinopathy: A clinical problem in patients with cancer pain.Experimental and therapeutic medicine · 2016Article
- Genetics of opiate addiction.Current psychiatry reports · 2014Review
- Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.The Journal of clinical investigation · 2012Review
- Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment.The Journal of infectious diseases · 2012Article
- The genetics of the opioid system and specific drug addictions.Human genetics · 2012Review
- The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.Alcoholism, clinical and experimental research · 2012Review
- Molecular mechanisms of opioid receptor-dependent signaling and behavior.Anesthesiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The mu-opioid receptor encoded by the gene OPRM1 plays a primary role in opiate, alcohol, cocaine and nicotine addiction. Studies using opioid antagonists demonstrate that the mu-opioid receptor (MOP-r) also mediates the hypothalamic-pituitary-adrenal (HPA) axis stress response. A common polymorphism in exon one of the MOP-r gene, A118G, has been shown to significantly alter receptor function and MOP-r gene expression; therefore, this variant likely affects HPA-axis responsivity. In the current study, we have investigated whether the presence of the 118AG variant genotype affects HPA axis responsivity to the stressor metyrapone, which transiently blocks glucocorticoid production in the adrenal cortex. Forty-eight normal and healthy volunteers (32 men, 16 women) were studied, among whom nine men and seven women had the 118AG genotype. The 118G allele blunted the adrenocorticotropic hormone (ACTH) response to metyrapone. Although there was no difference in basal levels of ACTH, subjects with the 118AG genotype had a more modest rise and resultant significantly lower ACTH levels than those with the prototype 118AA at the 8-hour time point (P < 0.02). We found no significant difference between genders. These findings suggest a relatively greater tonic inhibition at hypothalamic-pituitary sites through the mu-opioid receptor and relatively less cyclical glucocorticoid inhibition in subjects with the 118G allele.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.